Group: Space-flown cell line (cellonaut).
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: ENCODE project common cell types; tier 2.
Part of: JFCR39 cancer cell line panel.
Part of: JFCR45 cancer cell line panel.
Part of: ICBP43 breast cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: NCI-60 cancer cell line panel.
Registration: Chiron Master Culture Collection; CMCC 10377 (CMCC #10377).
Doubling time: 1.8 days (PubMed=9671407); 80 hours (PubMed=25984343); 31.2 hours (PubMed=22628656); 25.4 hours (NCI-DTP); ~50 hours, with a range of 30-72 hours (DSMZ); ~38 hours (PBCF).
HLA typing: A*02:01:01; B*18,44; C*05; DPB1*02:01:02,04:01; DQB1*02:01,06:02; DRB1*03,15 (PubMed=15748285).
HLA typing: A*02:01,02:01; B*18:01,44:02; C*05:01,05:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=25960936).
Microsatellite instability: Stable (MSS) (PubMed=12661003; PubMed=23671654; Sanger).
Sequence variation: Homozygous for CDKN2A deletion (PubMed=19593635).
Sequence variation: Heterozygous for PIK3CA p.Glu545Lys (c.1633G>A) (PubMed=17088437; PubMed=19593635; PubMed=28889351).
Sequence variation: Has no TP53 mutation (PubMed=15900046).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep phosphoproteome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: Glycoproteome analysis by proteomics.
Omics: H3K27ac ChIP-seq epigenome analysis.
Omics: H3K27me3 ChIP-seq epigenome analysis.
Omics: H3K36me3 ChIP-seq epigenome analysis.
Omics: H3K4me3 ChIP-seq epigenome analysis.
Omics: H3K9me3 ChIP-seq epigenome analysis.
Omics: lncRNA expression profiling.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: Myristoylated proteins analysis by proteomics.
Omics: N-glycan profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Omics: Virome analysis using proteomics.
Genome ancestry: African=0.74%; Native American=0%; East Asian, North=4.2%; East Asian, South=0%; South Asian=0%; European, North=56.91%; European, South=38.15% (PubMed=30894373).
Anecdotal: This is the first hormone-responsive breast cancer cell line to have been established.
Anecdotal: Helen Mallon (sister Catherine Frances), the patient from which this cell line is derived was a nun (Sister Catherine Frances) at the Immaculate Heart of Mary Convent in Monroe, Michigan.
Anecdotal: Have been flown in space on Foton-12 to study cytoskeleton architecture in microgravity (PubMed=11292682; PubMed=15002416).
Misspelling: MFC-7; Occasionally.
Discontinued: ATCC; CRL-12584.
Discontinued: JCRB; NIHS0200.
Derived from metastatic site: Pleural effusion.
DT Created: 04-04-12; Last updated: 05-07-19; Version: 31